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Abstract 
Cancers are serious life-threatening diseases which annually are responsible for millions of deaths across the world. 
Despite many developments in therapeutic approaches for affected individuals, the rate of morbidity and mortality 
is high. The survival rate and life quality of cancer patients is still low. In addition, the poor prognosis of patients and 
side effects of the present treatments underscores that finding novel and effective complementary and alternative 
therapies is a critical issue. Melatonin is a powerful anticancer agent and its efficiency has been widely documented 
up to now. Melatonin applies its anticancer abilities through affecting various mechanisms including angiogenesis, 
apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress. Regarding the implication of mentioned 
cellular processes in cancer pathogenesis, we aimed to further evaluate the anticancer effects of melatonin via these 
mechanisms.
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Introduction
As the second cause of mortality worldwide, new cases of 
cancer have recently been reported to increase by 2025 
(approximately 19.3 million annually) [1]. Cancer growth 
control, complete eradication and preventing its inci-
dence are main purposes for cancer-associated investiga-
tions. Chemotherapy, radiotherapy and surgery are the 
major conventional anticancer treatments. The restricted 
efficiency of these treatments as well as their dangerous 
side effects have forced researchers to find novel effective 
anticancer therapies based on herbal extracts and natural 
compounds as single or combined therapies [2–4].
Melatonin, a multifunctional pleiotropic neurohor-
mone secreted by the pineal gland and other organs 
including bone marrow, retina, and skin. It is an immune 
regulatory agent and powerful antioxidant with a capabil-
ity of preventing cell death in oxidative stress situations. 
[5, 6]. Moreover, melatonin interrupts cell death mecha-
nisms, inflammation, and redox activity probably result-
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Furthermore, in addition to diverse therapeutic poten-
tials for several diseases [8, 9], melatonin has been shown 
to possess anticancer abilities against skin cancer [10], 
glioma [11], lung cancer [12], gastrointestinal cancers 
[13], gynecological cancers [14, 15], and hematological 
cancers [16, 17]. Although mechanistic impacts of mela-
tonin on various cancers have been widely demonstrated, 
in the present review we discuss anticancer effects of 
melatonin with focusing on molecular pathways includ-
ing angiogenesis, apoptosis, autophagy, endoplasmic 
reticulum stress, and oxidative stress.
Melatonin, a neurohormone with a broad spectrum 
functions
Monitoring of circadian rhythm is one of the several 
properties of melatonin, which also possesses oncos-
tatic, vasoregulation, antioxidant, anti-inflammatory, and 
immunomodulatory abilities [18, 19]. It has been dem-
onstrated that the normally enhanced melatonin levels at 
night help in the organization of homeostatic metabolic 
rhythms of targeted organs and systems [20]. Of note, 
disruption of circadian rhythm has been shown as one of 
the contributing factors in cancer progression and devel-
opment [21].
Melatonin, as an antioxidant agent, scavenges free radi-
cals. Melatonin has protective effects on neurodegenera-
tive disorders, epilepsy, and cancer through inhibiting 
oxidative stress in  vitro and in  vivo [22, 23]. Melatonin 
increases the activity and expression of enzymes, includ-
ing catalase, superoxide dismutase and glutathione 
peroxidase, implicated in antioxidant abilities [24, 25]. 
Melatonin also has anti-inflammatory impacts and 
attenuates pathogenic inflammation through modulat-
ing different pathways, including reducing the secretion 
of tumor necrosis factor-alpha (TNF-α), interleukin-1 
(IL-2) and interferon-gamma (IFN-γ), and enhancing the 
amounts of IL-4, IL-10 and IL-27. Melatonin alleviates 
pro-inflammatory cytokines secretion via suppressing 
nuclear factor kappa B (NF-κB) [26–28]. In addition, in 
neurodegenerative disorders, melatonin blocks cycloox-
ygenase-2 (COX-2) expression, a pro-inflammatory 
mediator [29]. Melatonin inhibits apoptosis through reg-
ulating Bax/Bcl2 and decreasing caspase-3 activity and 
expression, proposing that melatonin modulates apop-
totic functions in the protection against malignancy and 
neurodegenerative disorders [30–32].
Melatonin  regulates multiple physiological and neural 
functions (Fig. 1). Among of them, effects on blood lipid 
profile, glycemic control, gestation, reproduction, and 
fetal development, neural protection, immune system, 
and cardiovascular system have been widely documented 
[33, 34]. Melatonin prevents the growth and promotion 
of spontaneous and chemically mediated breast tumors 
[35, 36]. Moreover, at physiological concentrations, mela-
tonin suppresses cell invasiveness and proliferation in 
breast cancer cells [37].
Melatonin and cancer: effect on different molecular 
mechanisms and cellular pathways
In this section we describe the effect of melatonin on 
oxidative stress and endoplasmic reticulum stress, and 
various signaling pathways including angiogenesis, 
apoptosis, autophagy affected by melatonin in different  
cancer cells (Fig. 2).
Melatonin and angiogenesis
Angiogenesis is a crucial event implicated in the pro-
gression of tumor as well as its metastasis [38]. Hypoxia 
in the central areas of solid tumor is a leading cause of 
angiogenesis via activation of angiogenic mediators 
[38, 39]. Vascular endothelial growth factor (VEGF), 
the specific mitogen of endothelial cells and the most 
active pro-angiogenic agent, is a powerful angiogenesis 
enhancer which increases vascular permeability. Numer-
ous data suggest that, in tumor development, anti-VEGF 
therapy has important roles in the suppression of tumor 
cell growth, leading to a considerable amelioration in 
progression-free survival [40]. Hypoxia-inducible fac-
tor-1 (HIF-1) is another key factor in angiogenesis, which 
modulates hypoxia-activated genes transcription and 
consists of HIF-1α and HIF-1β heterodimer. The α sub-
unit of HIF-1 is stabilized under hypoxia and degraded 
under normoxic situations, however, HIF-1β is expressed 
constitutively [41].
Melatonin has been shown to have regulatory role in 
angiogenesis process [42]. In other words, melatonin 
possesses various impacts on neovascularization under 
diverse pathological and physiological situations. In skin 
lesions, gastric ulcers, and some physiologic events, mel-
atonin promotes angiogenesis, while in a hypoxic envi-
ronment, in age-related ocular diseases, and in tumors 
melatonin suppresses neovascularization in tissues [43].
Melatonin exerts its antitumor potentials via inhib-
iting HIF-1-induced angiogenesis [44]. Furthermore, 
melatonin inhibits the accumulation of HIF-1α through 
suppressing the formation of ROS and the sphingosine 
kinase 1 (SPHK1) pathway in prostate cancer cells under 
hypoxic conditions [45]. Melatonin plays an impor-
tant role in the paracrine interaction between proximal 
endothelial cells and malignant epithelial cells by a down-
modulatory effect on the expression of VEGF in breast 
tumor cells, which reduces VEGF levels around endothe-
lial cells [46].
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Of note, anti-angiogenic potential of melatonin is a 
key factor resulting in the inhibition of proliferation of 
cancer cells, as demonstrated in various investigations. 
For instance, melatonin attenuates proliferation  of 
prostate cancer cells triggered by epidermal growth 
factor [47]. Melatonin also hampers vasculogenic mim-
icry of oral cancer cells via inhibition of ROS-activated 
Akt and ERKs signaling pathway implicating the HIF-α 
pathway [48]. Melatonin up-regulates TGF-β1 expres-
sion in tumor tissues during the inhibition of gastric 
cancer tumor growth process [49]. Furthermore, apop-
totic and anti-proliferative effects of melatonin on 
breast cancer cells are mediated by the simultaneous 
activation of the Apaf-1/caspase-dependent apoptotic 
pathway and the inhibition of PI3K/Akt, p300/NF-κB, 
and COX-2/PGE2 signaling pathways [32].
Endothelin-1 is a peptide acting as a survival factor 
in colon cancer, promoting angiogenesis and mediat-
ing cell proliferation. Melatonin suppresses endothelin-1 
mRNA expression. Also, melatonin blocks the activity of 
endothelin-1 promoter modulated by NF-κβ and FoxO1 
[50].  Melatonin  represses ROCK-1, VEGF and HIF-1α 
genes expressions in oral cancer [51]. Melatonin alters 
the expression of inflammatory and angiogenic proteins 
in both co-culture and monoculture of cancer cells and 
cancer-associated fibroblasts [52]. Melatonin suppresses 
tumor angiogenesis and the growth of gastric cancer 
cells in tumor-bearing nude mice. Moreover, melatonin 
decreases the expression of VEGF and HIF-1α at trans-
lational and transcriptional levels within gastric cancer 
cells during tumorigenesis [53]. Reduced serum levels of 
VEGF have been reported in cancer subjects treated with 
Fig. 1 Melatonin with a broad spectrum functions
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melatonin [54]. Vimalraj et  al. [55] showed that mela-
tonin upregulates miR-424-5p expression in osteosar-
coma cells suppressing VEGFA. Furthermore, it inhibits 
tumor angiogenesis, regulating surrounding endothelial 
cells migration and proliferation, and angiogenic growth 
factors and the morphology of blood vessels E (Table 1).
Melatonin and oxidative stress
In normal cellular condition, there is a balance between 
the production of oxidants, so called reactive oxygen 
species (ROS), and their neutralizing compounds, named 
antioxidants. The state of excess ROS, in which the oxi-
dant content of the cells dominates the neutralizing 
capacity of antioxidants, is defined as oxidative stress 
[56, 57]. Sustained oxidative stress increases the risk of 
cancer development either through inducing mutagen-
esis or by promoting the expression of proto-oncogenes 
such as cyclin D1. It also plays a signaling role in the 
Fig. 2 Effects of melatonin on various molecular mechanisms and cellular pathways
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activation of several genes involved in the cancer pro-
gression including the mitogen-activated protein kinase 
(MAPK), extracellular signal-regulated kinase (ERK) and 
JUN N-terminal kinase (JNK) [58, 59].
Melatonin role as a natural ally against oxidative stress 
has been revealed in many in  vitro and in  vivo studies. 
Detoxification of oxidants by melatonin is triggered by 
several direct or indirect mechanisms. In direct scenario, 
melatonin neutralizes the oxidants by its nonrecep-
tor‐mediated free radical scavenging capacity. As indi-
rect scenario, melatonin reduces the oxidative content 
through several mechanisms such as activating anti-oxi-
dative enzymes and suppressing pro‐oxidative enzymes. 
It also stabilizes the mitochondrial inner membrane, 
thereby maintaining mitochondrial integrity leading to a 
reduced electron leakage and ROS generation [60, 61].
The inducing role of oxidative stress in cancer progres-
sion and preventive role of melatonin in the production 
and function of oxidants indicated a possible oncostatic 
property for melatonin [62]. Subsequently, it was revealed 
that melatonin reduces the oxidative damage to cellular 
components under conditions where toxic oxygen deriva-
tives are acknowledged to be released [63, 64]. Moreover, 
in  vitro studies demonstrated that melatonin treatment 
reduces the amount of oxidative contents in a variety 
of cancer cells, which was further supported by in  vivo 
studies (Table 2).
Melatonin and endoplasmic reticulum stress
Endoplasmic reticulum (ER) is an entry site for secre-
tory proteins  and most  integral membrane proteins for 
proper folding and covalent modifications to assemble 
into a functional complex. In addition to the processing 
of proteins, ER is involved in various cellular functions 
including lipid synthesis, fatty acid turnover, detoxifica-
tion,  Ca2+ homeostasis. The ER network extends into all 
cell compartments to sense intrinsic and extrinsic pertur-
bations and integrate the stress signals for maintenance 
of cellular homeostasis to preserve proper  cellular  and 
organismal function [65, 66]. However, the ER function 
can be impacted and disturbed by a multitude of exog-
enous and endogenous factors, leading to the accumula-
tion of mis/unfolded proteins in the ER. This causes the 
imbalance between the client proteins load in the lumen 
of ER and the folding capacity of this organelle leading 
to the failure of the  ER  to  cope  with unusual  high pro-
tein  folding  load, which is termed ’ER stress’ [67]. To 
restore protein homeostasis, an adaptive signal trans-
duction pathway called the unfolded protein response 
(UPR) is activated to induce compensatory responses to 
stressors  for recovering normal ER function [68]. Sign-
aling proteins sensing UPR include inositol-requiring 
protein-1α (IRE1α), activating transcription factor 6α 
(ATF6α) and protein kinase RNA (PKR)-like ER kinase 
(PERK). In nonstressed cells, UPR stress sensors are 
maintained in an inactive state through direct binding 
to the ER chaperone proteins, Bip (78-kDa glucose regu-
lated protein, GRP78). Upon  ER stress, aggregation of 
misfolded proteins leads to the dissociation of UPR sen-
sors from Bip, which causes activation of UPR signals 
[69]. Although activation of UPR signaling pathways is 
a cellular strategy to increase survival, this pathway will 
instead activate cell death signaling pathways when the 
intensity or duration of cellular stress increases. There-
fore, certain anti-cancer patterns may activate ER stress/
UPR pathway to induce apoptosis in cancer cells [70].
Melatonin induces mitochondria-mediated apoptosis 
in colorectal cancer cells through reducing the expres-
sion of  PrPC and PINK1 resulting in the enhancement 
of superoxide production and induction of ER stress 
[71]. Melatonin also ameliorates ER-stress mediated 
insulin resistance. ER stress induces autophagy in pan-
creatic β cells, which this pathway plays an important 
role in insulin production and secretion. In the glucose 
analog 2-DG-treated rat insulinoma INS-1E cells, mela-
tonin reduces insulin production via ER stress-induced 
autophagy [72]. Combination of melatonin with ER stress 
inducer tunicamycin increases the sensitivity of cancer 
cells to apoptosis through inhibiting the expression of 
COX-2 and increasing the Bax/Bcl-2 ratio and CHOP 
levels [73]. Selective inhibition of ATF-6 by melatonin 
results in the suppression of COX-2 production and 
enhancement of cancer cells to ER-stress induced apop-
tosis [74].
Melatonin increases apoptosis through enhancing 
caspase-3, -8 and -9 activities, Bax/Bcl-2 ratio, PARP 
cleavage and cytochrome c, p53 and Fas-L proteins con-
centrations in hepatocellular carcinoma, which this effect 
is mediated by the elevation of ER stress characterized 
by up-regulation of ATF6, CHOP and Bip [75]. Further-
more, melatonin increases the sensitivity of hepatocel-
lular carcinoma cells to sorafenib through targeting the 
PERK-ATF4-Beclin1 pathway [76]. The same results 
have been reported in gastric cancer; melatonin inhibits 
cell proliferation through inducing activation of the IRE/
JNK/Beclin1 signaling [77].
Melatonin in combination with the ER stressor  thap-
sigargin  increases the expression level of nuclear mam-
malian RNA-binding protein (HuD) resulting in the 
reduction of intracellular biosynthesis of insulin. Sup-
pression of AKT/PI3K pathway and induction of nuclear 
mTOR (Ser2481, Ser2448) expressions by melatonin 
sensitizes rat insulinoma INS-1E cells to insulin through 
increasing the expression of insulin receptor substrate 
[78]. In contrast with these reports, melatonin has been 
reported to inhibit tunicamycin-induced ER stress in 
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Table 2 Melatonin acts as an antioxidant in cancer models
Cancer Melatonin dose/
concentration
Key findings Model Cell line/animal Refs.
Breast cancer 1 μM
5, 10, 50 mg/kg
Limited paclitaxel-mediated 
mitochondrial dysfunc-
tion and protected against 
paclitaxel-mediated neuro-
pathic pain
In vitro, in vivo MCF-7
Male and female Sprague 
Dawley rats
[198]
Neuroblastoma 10 μM Reduced oxaliplatin-induced 
neurotoxicity
In vitro SH-SY5Y [199]
Breast cancer 0.3 mM Supported doxorubicin effects 
by apoptosis and TRPV1acti-
vation, and through mediat-
ing cancer cell death
In vitro MCF-7 [200]
Cervical cancer 1 mM Enhanced cisplatin-mediated 
cytotoxicity and apoptosis
In vitro HeLa [163]
Lung cancer 1 nm, 1 μm, 1 mm Exerted immunomodulatory 
effects
In vitro SK‐LU‐1 [201]
Pancreatic cancer 26.8 mg capecitabine and melatonin 
provided an amelioration in 
antioxidant status and syn-
ergistic antitumoral effects
In vivo Male Syrian hamsters [202]
Leukemia 1 mM Protected healthy cells from 
chemotherapy-mediated 
ROS production and 
induced tumor cell death
In vitro HL-60 [180]
Hepatocellular carcinoma 1, 100 μM The responses of angiogenic 
chemokine genes to mela-
tonin were determined by 
the characteristics of cancer 
cells
In vitro HCC24/KMUH, [203]
Pancreatic cancer 53.76 mg Exerted more potent benefi-
cial effects than celecoxib 
on the decrease in tumor 
nodules, oxidative stress and 
death
In vivo Male Syrian hamsters [204]
Breast cancer 2.5 mg/kg Antioxidant effects In vivo Female Sprague Dawley rats [205]
Pancreatic cancer 26.88, 53.76 mg Decreased oxidative damage 
and cancer nodules medi-
ated by BOP in the pancreas
In vivo Male Syrian hamsters [206]
Cervical cancer 10–1000 μM This study showed melatonin 
effects on radiotherapy is 
dose-dependent
In vitro HeLa [207]
Hepatocellular carcinoma 20 mg/kg Fostered the survival and 
therapeutic potential of 
MSCs in HCC, by inhibi-
tion of oxidative stress and 
inflammation as well as 
apoptosis induction
In vivo Adult female rats [120]
Cervical cancer 10 μM Enhanced TNF-α-mediated 
cervical cancer cells mito-
chondrial apoptosis
In vitro HeLa [14]
Bladder cancer 1 mM
100 mg/kg
Inhibited the growth, migra-
tion, and invasion of cancer 
cells
In vivo, in vitro HT1197, HT1376, T24, RT4
Male C57B/L6 mice
[208]
Lung cancer 0.25–2.5 mM Enhanced palladium-nanopar-
ticle-induced cytotoxicity 
and apoptosis
In vitro A549, H1299 [209]
Lymphoma, cervical cancer, 
hepatoblastoma, gastric 
cancer, breast, colon and 
lung adenocarcinoma,
0–2 mM Sensitizees shikonin-mediated 
cancer cell death induced 
by oxidative stress
In vitro U937, HeLa, Hep-G2, AGS, 
MCF-7, SW480, A549
[210]
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human hepatocellular carcinoma cells and increase the 
response of these cells to cytotoxic effects of doxorubicin; 
this is accompanied by inhibition of the PI3K/AKT path-
way, elevation of CHOP and reduction of Survivin [79]. 
These evidences suggest that melatonin could improve 
the toxic effect of anti-cancer agents on cancer cells 
through regulating ER stress in cells (Table 3).
Table 3 Melatonin suppressive effects on various cancers via regulation of ER stress
Cancer Melatonin dose/
concentration
Effect on ER stress Key findings Model Cell line/animal Refs.
Gastric cancer 1, 2, 3 mM
50 mg/kg
Activate Melatonin-mediated 
inhibition of cancer cell 
proliferation is induced 
by the IRE/JNK/Beclin1 
signaling activation
In vitro, in vivo AGS, SGC-7901 cells
Male BALB/c nude mice
[77]
Lung, liver and cervical 
cancer
2 mM Activate Induced apoptosis by 
ROS generation and 
JNK activation
In vitro HepG2, A549, HeLa [211]
Hepatocellular carcinoma 10–5 M - enhanced HCC sensitivity 
to sorafenib through 
suppressing autophagy
In vitro HepG2, 7721, Huh7, LO2 [76]






Hepatoma 10–7-10–3 mM - Melatonin was shown as 
a novel selective ATF-6 
inhibitor that can sensi-
tize human hepatoma 
cells to ER stress induc-
ing apoptosis
In vitro HepG2 [74]
Insulinoma 100 μM Activate Melatonin-induced 
insulin synthesis 
involved autophagy 
and EDC3 protein in rat 
insulinoma cells and 
subsequently resulted 
in a resuction in intra-
cellular production of 
insulin
In vitro INS-1E [72]
Hepatocellular carcinoma 1 mg/kg/d Activate Activated ER stress and 
apoptosis
In vivo Male Wistar rats [75]
Insulinoma 10, 50 μM - Decreased nuclear and 
cellular expressions of 
p85α
Decreased cellular 
expression of HuD and 
led to a reduction in 
cellular insulin level and 
rise in insulin secretion
In vitro INS-1E [78]
Hepatocellular carcinoma 10–3 M Inhibit Attenuated ER stress-
mediated resistance to 
doxorubicin by down-
regulating the PI3K/AKT 
pathway, enhancing 
CHOP levels and reduc-
ing Survivin levels
In vitro HepG2, SMMC-7721 [79]
Hepatoma 10–9,  10–7,  10–5,  10–3 μM Activate Sensitized cancer cells 




the levels of CHOP and 
reducing the Bcl-2/
Bax ratio
In vitro HepG2, HL-7702 [73]
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Melatonin and autophagy
Autophagy is a complicated process maintaining intra-
cellular homeostasis by eliminating degraded proteins 
and organelles during cellular stress. Autophagy is princi-
pally considered as a pro-survival process, but, excessive 
or inappropriate autophagy contributes to the cell death, 
a process known as autophagic cell death or type II pro-
grammed cell death [80].
Autophagy is a complicated process, which consists 
of  five  sequential  steps, including: (a) initiation com-
plex formation and double-membrane phagophore 
(nucleation) maturation; (b) membrane elongation and 
autophagosome formation sequestering cargo; (c) fusion 
with lysosome; (d) inner membrane disruption lead-
ing to degradation of cargo by hydrolases; and (e) mac-
romolecular component utilization [81]. These steps of 
the autophagy pathway are regulated by more than 35 
autophagy related genes (ATGs) and proteins most of 
which function in complexes. The initiation phase is regu-
lated by Unc-51-like kinase1 (mammalian homologues of 
Atg1, ULK1)–Atg13–Atg101–FIP200 (mammalian hom-
ologues of Atg17) protein complex. Unc-51-like kinase1 
phosphorylates and activates  Beclin-1  (mammalian 
homologue of  Atg6). Beclin-1 is a part of multiprotein-
complex, class III PI3-kinase Vps34–p150 (mammalian 
homolog of Vps15)–Atg14-like protein (Atg14L)–Bec-
lin-1, promoting nucleation [81–83]. The elongation 
phase is regulated by two ubiquitin-like conjugation sys-
tems, Atg12 and LC3 (mammalian homologue of Atg8). 
In the first conjugation system, Atg12 is activated by Atg7 
(E1-like enzyme), transferred to Atg10 (E2-like enzyme) 
and conjugated to Atg5. The Atg12–Atg5 conjugates fur-
ther couples with Atg16 (Atg16L  in mammals) to form 
the E3-like complex. In the LC3 conjugation system, LC3 
is cleaved by a cysteine protease, Atg4, forming LC3-I. 
Thereafter, LC3-I is activated by Atg7 (E1-like enzyme), 
transferred to Atg3 (E1-like enzyme) and conjugated to 
phosphatidylethanolamine (PE) to form LC3-II; this pro-
cess is facilitated by the E3-like complex. This lipidated 
form of LC3, LC3-II, is recruited to the autophagosome 
membrane. Finally, the Atg9 dependent pathway pro-
motes autophagosome membrane expansion [81–83].
Cargo sequestration can be selective or non-selective; 
the selectivity is based on autophagy receptors such as 
P62/SQSTM1, NBR1, NDP52, NIX/BNIP3L, BNIP3 and 
FUNDC1 [82]. Fusion of autophagosome with lysosome 
is the next step. The inner vesicle is degraded by lyso-
somal hydrolases, including  cathepsin B, D (a homolog 
of proteinase A), and L. The degradation products are 
released to the cytosol and used in different anabolic 
pathways [84]. ER stress-induced activation of UPR 
pathways promotes induction of autophagy [85]. Acti-
vated PERK/ATF4 pathway up-regulates the expression 
of ATG genes including ATG5, ATG7, and ATG10 [86]. 
The conversion of LC3-I conversion to LC3-II is also 
induced by PERK pathway [87]. Activation of IRE1α 
pathway induces the expression of Beclin1 and the phos-
phorylation of Bcl-2 by JNK, which subsequently results 
in the Bcl-2–Beclin 1 dissociation [88–90]. The release 
of  Ca2+ from ER to cytosol triggers autophagy pathway 
through activating several mechanisms including (I) inhi-
bition of mTOR by  Ca2+/calmodulin dependent kinase 
kinase-β-mediated activation of AMP-activated protein 
kinase (AMPK) [91], and (II) dissociation of Bcl-2–Bec-
lin 1 by inducing death-associated protein kinase (DAPK) 
3-mediated Beclin 1 phosphorylation [92].
Melatonin  has a modulatory effect on  autophagy  in 
various cell types and different conditions. Melatonin 
indirectly modulates autophagy through affecting oxida-
tive stress,  ER stress  and inflammation [69]. Melatonin 
enhances the effectiveness of cisplatin and radiotherapy in 
head and neck squamous cell carcinoma, which this effect 
is mediated by the excessive activation of mitochondria 
leading to the over-production of ROS and subsequent 
induction of autophagy and apoptosis [93]. Melatonin also 
increases cytotoxic effects of rapamycin in cancer cells. 
Combination of rapamycin and melatonin suppresses 
AKT/mTOR pathway activation, which this effect leads 
to the enhancement of mitochondrial function and ROS 
production resulting in the induction of apoptosis and 
mitophagy [94]. Melatonin induces autophagy in clear cell 
renal cell carcinoma through activating transcriptional 
coactivator peroxisome proliferator-activated receptor 
gamma coactivator 1A (PGC1A) and uncoupling protein 
1 (UCP1); this is associated with the elimination of lipid 
deposits without generating ATP, which subsequently 
leads to the tumor size reduction [95].
Melatonin reduces the viability liver cancer cells through 
transient induction autophagy by up-regulating JNK phos-
phorylation. However, ATG5 silencing sensitizes cancer 
cells to melatonin-induced apoptosis. This suggests that 
modulation of autophagy by melatonin has dual effect 
on cell death [96]. Similarly, disruption of autophagy 
sensitizes glioblastoma cells and tongue squamous cell 
carcinoma to melatonin-induced apoptosis [97]. Mel-
atonin-induced autophagy is suggested to be mediated 
by activation of melatonin membrane receptor in tongue 
squamous cell carcinoma and suppression of melatonin 
membrane receptor-dependent autophagy may be strategy 
for treatment of tongue squamous cell carcinoma [98].
Several studies indicate that melatonin may induce 
apoptosis in cancer cells through inhibiting autophagy 
pathway. Melatonin down-regulates Beclin-1 and p62 
expressions and LC3B-II/LC3B-I ratio in colitis-associ-
ated colon carcinogenesis in mice; this effect is associ-
ated with the increased level of Nrf2 and its downstream 
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antioxidant enzymes including NAD(P)H:quinone oxi-
doreductase (NQO-1) and heme oxygenase-1 (HO-1). 
These suggest that the ameliorative effect of melatonin 
on inflammation and oxidative stress results in the reduc-
tion of autophagy [99]. Induction of ER stress is associ-
ated with the activation of autophagy in sorafenib-treated 
hepatocellular carcinoma cells, which this contributes to 
the resistance of cancer cells to apoptosis. Combination 
of melatonin with sorafenib inhibits ER stress-related 
autophagy through suppressing the PERK-ATF4-Beclin1 
pathway leading to the sensitivity of hepatocellular car-
cinoma cells to sorafenib [76]. Co-stimulation of cancer 
cells with cisplatin and melatonin induce apoptosis in 
HeLa cells, which this effect is accompanied by inactivat-
ing mitophagy via blockade of JNK/Parkin pathway [100]. 
In contrast with this report, melatonin has been found to 
reversed the effects of cisplatin in HepG2 cells through 
suppression of mTOR and DNA excision repair cross 
complementary 1 (ERCC1) proteins expressions and up-
regulation of Beclin-1 and LC3II expressions [101]. Taken 
together, different effects of melatonin on autophagy may 
be related to type of cancer cells, the stage of cancer and 
dose of melatonin (Table 4).
Melatonin and apoptosis
The balance between cell proliferation and death in tissues 
is maintained by apoptosis, a classical form of programmed 
cell death. Apoptosis is associated with the disassembly of 
apoptotic cells  into membrane-enclosed vesicles, which 
are removed by macrophages without  inducing inflam-
matory responses. Apoptosis  is mediated by  two princi-
ple signaling pathways, including extrinsic and intrinsic 
pathways [102]. The extrinsic apoptotic signaling path-
ways, defined as death receptor pathways, are initiated by 
the interaction of transmembrane death receptors (Fas, 
TNFR1, DR4 and DR5) with extracellular ligands (FasL, 
TNFα, TRAIL, and TNFSF10) resulting in the activation 
of adaptor proteins such as Fas-associated death domain 
(FADD). Activated FADD recruits  initiator caspases (cas-
pase 8 and caspase 10) to form the death-inducing signal 
complex (DISC). Formation of DISC leads to the proteo-
lytic activation of  caspase  8, which is the main  initiator 
caspase of the extrinsic apoptotic signaling pathway. Cas-
pase 8 activates executioner caspases (caspase 3, caspase 6, 
and caspase 7) and cleaves Bid, a BH3-only domain mem-
ber of the B cell lymphoma-2 (Bcl-2) family. Truncated Bid 
(tBid) translocates to  mitochondria  and activates other 
proapoptotic Bcl-2 family members including Bak or Bax 
[102, 103].
The intrinsic apoptosis pathway, defined as mitochon-
drial-mediated apoptotic pathway, is activated by exog-
enous and endogenous stimuli such as DNA damage, 
oxidative stress, chemotherapy and radiotherapy. This 
apoptosis pathway is mediated by insertion of pro-apop-
totic Bcl-2 family members (Bax/Bak) into mitochondrial 
membrane leading to the mitochondrial  outer mem-
brane permeabilization and release of pro-apoptotic fac-
tors such as cytochrome c, Smac/DIABLO, the nuclease 
EndoG, the oxidoreductase AIF, and the protease HtrA2/
Omi [104]. Therefore, activation of pro-apoptotic Bcl-2 
family members (Bax/Bak) is essential for cancer ther-
apy. In contrast, elevation of anti-apoptotic Bcl-2 fam-
ily proteins inhibits apoptosis in cancer cells through 
heterodimerization with Bax/Bak preventing the release 
of pro-apoptotic factors from mitochondria; this could 
result in the resistance of cancer cells to immune-sur-
veillance [105, 106]. Once in the  cytosol, cytochrome 
c combines with Apaf–1 and procaspase-9 to drive the 
assembly of the apoptosome; this molecular platform 
activates caspase 9, which this is followed by the acti-
vation of caspase-3 cascade of apoptosis [107]. Smac/
DIABLO and HtrA2/Omi induce apoptosis through 
degrading inhibitor of apoptosis protein (IAP) family, 
neutralizing the inhibitory effect of  IAPs on caspases 
[108]. The nuclease EndoG and the oxidoreductase AIF 
translocate to the nucleus, where they trigger internu-
cleosomal DNA fragmentation independently of caspases 
[109].
As mentioned earlier, UPR signaling may promote the 
apoptotic pathways. Upon ER stress, apoptosis signal-
regulating kinase 1 (ASK1) is recruited by IRE1α-TNF 
receptor-associated factor 2 (TRAF2) complex, caus-
ing  activation  of  ASK1  and the downstream JNK path-
way. Activation of JNK results in the phosphorylation of 
Bcl-2 and Bax; phosphorylation  of Bcl-2 family sup-
presses antiapoptotic activity of Bcl-2, while induces 
mitochondrial translocation of Bax and activation of 
apoptosis pathway. Activated JNK also activates C/EBP 
homologous protein (CHOP), a stress-induced transcrip-
tion factor inducing the expression of pro-apoptotic Bcl-2 
family members. Furthermore, IRE1α-TRAF2 complex 
triggers the activation of caspase-12, which this caspase 
translocates from the ER to the cytosol, where it activates 
caspase-9, independent from the apoptosome pathway 
[110]. Furthermore, Activated PERK phosphorylates 
eIF2α, promoting the expression of activating transcrip-
tional factor 4 (ATF4); ATF4 translocates to the nucleus 
where it induces CHOP expression [111].
Melatonin is reported to restrict tumor growth and can-
cer cell proliferation through inducing apoptosis in cancer 
cells (Table 5). As a powerful antioxidant melatonin inhib-
its ROS-induced activation of extracellular-regulated pro-
tein kinases (ERKs) and Akt pathways which are involved 
in the cancer cell survivor; inactivation of ROS-dependent 
Akt signaling contributes to the down-regulation of cyclin 
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D1, PCNA, and Bcl-2 and up-regulation of Bax in cancer 
cells [48]. Inhibition of MDM2 expression is a mechanism 
by which melatonin induces apoptosis through upregu-
lating the activity of caspase-3 and -9; MDM2 is an E3 
ubiquitin ligase, which negatively regulates the p53 tumor 
suppressor [112, 113]. Under hypoxic conditions, tumor 
cells become resistant to TRAIL-induced cell apoptosis; 
this contributes to the up-regulation of anti-apoptotic 
protein expression and reduction of pro-apoptotic pro-
tein expression. Treatment with melatonin blocks hypoxic 
responses leading to the induction of apoptosis in TRAIL 
resistance tumor cells by the regulation of mitochondrial 
transmembrane potential and induction of Bax trans-
location [114]. Melatonin inhibits cancer cell growth by 
increasing cell cycle arrest in the G2/M phase, which this 
effect is coincident with the induction of apoptosis through 
up-regulating the expression of p53, p21, caspase-3/8/9, 
PARP, cytochrome c, Bax, JNK 1,-2 and -3 and p38 MAPKs 
in cancer cells [115]. Melatonin triggers two distinct apop-
totic processes including TGFβ1 and caspase-independent 
early apoptosis and TGFβ1 and caspases-dependent late 
apoptosis. Early apoptosis is associated with the elevation 
level of p53/MDM2 ratio and up-regulation of AIF release; 
this process is independent to caspase activity or cleavage 
of PARP. Late apoptosis is associated with elevation of cas-
pases-9 and -7 activity and cleaved-PARP level as well as 
reduction of Bcl-2/Bax ratio [116]. Melatonin also induces 
apoptosis through simultaneous suppression of COX-2/
PGE2, p300/NF-κB, and PI3K/Akt signaling pathway. Inhi-
bition of these pathways leads to the induction of Apaf-1 
expression triggering cytochrome c release, and caspase-3 
and -9 activation and cleavage [32].
Melatonin induces dephosphorylation and nuclear 
import of histone deacetylase 4 (HDAC4) in cancer cells; 
melatonin exerts this effect through inactivation of  Ca2+/
calmodulin-dependent protein kinase II alpha (CaMKIIα), 
leading to the H3 acetylation on Bcl-2 promoter and sub-
sequent reduction of Bcl-2 expression [117]. Furthermore, 
inhibition of HDAC9 expression is a mechanism of mela-
tonin to promote apoptosis in non-small cell lung cancer; 
the increased level of HDAC9 in patients with non-small 
cell lung cancer is correlated with worse overall survival 
and poor prognosis [118]. Melatonin promotes TNF-α-
mediated apoptosis via inhibiting mitophagy in tumor cells. 
Since activation of mitophagy suppresses mitochondrial 
apoptosis, inhibition of mitophagy by melatonin results in 
the repression of mitochondrial potential, elevation of ROS 
generation, augmentation of mPTP opening rate and up-
regulation of cytochrome c expression and caspases activ-
ity. Melatonin inhibits autophagy in tumor cells through 
inhibiting CaMKII activity leading to the suppression of 
Parkin expression [119]. In diethylnitrosamine (DEN)-
induced hepatocellular carcinoma (HCC), melatonin 
increases therapeutic potential of mesenchymal stem cells 
(MSCs) through reduction of oxidative stress and inflam-
mation, and induction of apoptosis [120].
Melatonin has been reported to increase therapeutic 
potential of anti-cancer agents, which this effect may result 
from its stimulatory effect on apoptosis. Co-treatment 
of melatonin and pterostilbene in colorectal cancer cells 
synergically enhances ROS production and apoptosis. 
Combination of these two agents upregulates the mRNA 
level of miR-25-5p, which this results in the activation of 
PARP and sex-determining region Y-Box10 (SOX10), and 
attenuation of Bcl-xL, neural precursor cell expressed 
developmentally downregulated protein 9 (NEDD9), and 
SOX9 expressions [121]. Melatonin synergically enhances 
anticancer potential of cisplatin through inducing apopto-
sis; melatonin increases the effect of cisplatin to the inhi-
bition of ERK phosphorylation and induction of 90-kDa 
ribosomal S6 kinase (p90RSK) and heat shock protein 27 
(HSP27) dephosphorylation [122]. Treatment with mela-
tonin enhances ER stress–mediated apoptosis in tunica-
mycin-treated cancer cells; this effect is associated with 
the down-regulation of COX-2 and Bcl-2 expressions and 
up-regulation of Bim, CHOP and Bax expressions [73]. 
Melatonin inhibits tunicamycin-induced COX-2 activation 
in tumor cells through inhibiting NF-ĸB and p38 MAPK 
activation and p65 nuclear translocation [123]. Combina-
tion of melatonin with phenylarsine oxide also induces 
endoplasmic reticulum stress-induced cell death, accom-
panied by JNK activation, PARP cleavage, ROS generation 
and caspase-3 activation [124].
Conclusions
This review summarizes the anti-carcinogenic poten-
tials of melatonin by evaluating various signaling path-
ways. Melatonin inhibits proliferation of cancer cells 
through triggering cell cycle arrest and causes cell 
death by induction of apoptosis. Melatonin suppresses 
metastasis angiogenesis, and proliferation of cancer 
cells through affecting various signaling pathways in 
tumor cells. Melatonin also regulates autophagy path-
way in cancer cell by affecting oxidative stress condition 
in tumor cells. These findings suggest that melatonin 
may increase the sensitivity of cancer cells to anti-can-
cer agents and may be a potential treatment for cancers 
either alone or in combination with other anti-cancer 
drugs. However, further clinical studies are needed to 
clarify the effect of this molecule in different cancers 
and obtain affective dose of melatonin for patients with 
cancer.
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